Digital therapeutics · Digestive health
Caelum Health
A Y Combinator company that pitched software as a replacement for irritable bowel syndrome drugs, then shipped a diet coaching app. Y Combinator’s own directory now marks it inactive, and the domain it once used belongs to someone else.
The thread that asked the hard question
On April 25, 2018 the founders posted their launch thread on Hacker News, describing Caelum as a digital therapeutic for stomach problems. It drew 56 points and 43 comments. Most were about price. Two were not.
One commenter walked through Ohio’s dietetics statute, quoted the line that “only licensed dietitians can practice dietetics,” and asked how an app that assessed nutritional needs and counseled patients could do that with no licensed dietitian in the loop. Another pointed at the company’s own words: calling the product a digital therapeutic for a named disease, that commenter argued, put it inside the definition of a medical device.
Both questions got answers. Neither got an FDA submission, a registered trial or a published paper. Eight years later, that is still the shape of the record.
The problem was real
Irritable bowel syndrome is common and stubborn. A 2024 review in Clinical Gastroenterology and Hepatology puts pooled worldwide prevalence at 4.1 percent under Rome IV criteria and describes quality of life losses comparable to diabetes and end stage renal disease. Caelum’s launch post used a wider figure, saying IBS “affects 15-20% of people.”
The behavioral case is strong on its own terms. A Rome Foundation Working Team Report published in Gastroenterology in 2022 groups five classes of brain gut behavior therapy and records more than 30 randomized controlled trials behind cognitive behavioral therapy for IBS, plus meta analysis support for gut directed hypnotherapy. A 2016 Monash University trial found hypnotherapy and the low FODMAP diet produced similar symptom relief, with hypnotherapy better on anxiety and depression scores.
That evidence belongs to the therapies. It does not transfer to a company by association, and Caelum never generated any of its own.
A brother and a sister
Lauren Kelley-Chew took a medical degree at the University of Pennsylvania after studying human biology and applied mathematics at Stanford, with earlier stops in private equity at Health Evolution Partners and Francisco Partners. Her brother Luke came from technology and business school. Crunchbase files the company under its Women Founded tag.
The pitch: the best IBS treatments are diet and lifestyle change, they work in trials, and almost nobody can execute them without continuous expert guidance most patients cannot afford. The app was the guidance, and a coach reachable by message was the core of it.
What was promised, and what was sold
At Y Combinator’s Summer 2017 Demo Day, TechCrunch summarized the pitch under the heading “Replace prescription drugs with software.” The company’s directory one liner said it treated “diseases where drugs don’t work.” Its long description called the product “the first clinically-proven digital treatment for digestive health and IBS.”
What shipped was narrower. The May 2018 homepage read “Caelum Health | Medicine Made Simple.” By April 2019 it read “Caelum Health | Diet Coaching That Fits Into Your Life,” promising coaching “for significantly less money than traditional dietitians.” The disease claim had become a convenience claim.
Then the captures stop mattering. From mid 2020 the domain served a Persian language marketing blog. By September 2023 it served a Chinese electronic materials manufacturer. Apple’s lookup service returns nothing for the iOS app identifier. As of September 24, 2026 the hostname does not resolve.
What is proven, and what is still claimed
| Evidence | What the record shows | Source type |
|---|---|---|
| FDA clearance | No 510(k), De Novo or premarket approval on record. The founders said in April 2018 that the product had not been subject to FDA regulation. | Not found |
| Registered trials | No study on ClinicalTrials.gov names the company or the product. The April 2018 launch post said a clinical trial would start soon. None appears. | Not found |
| Peer reviewed papers | No PubMed record naming Caelum Health or its product. | Not found |
| “First clinically-proven digital treatment” | The company description used this phrase. No trial, publication or regulatory submission supports it. | Claim without record |
| Demo Day claims, August 2017 | TechCrunch reported the company saying its treatments were three times more effective than prescription drugs and that it had pilots with seven of the ten largest health systems. No health system was ever named, and no later report confirms one. | Unverified claim |
| Therapy actually delivered | The shipped product guided patients through the low FODMAP diet with human coaches. Nothing in the record shows Caelum delivering gut directed hypnotherapy or GI focused cognitive behavioral therapy, the two brain gut therapies with the deepest trial base. | Not found |
| Clinician licensure | The 2018 thread raised state dietetics licensing and the medical device definition. The founders said lawyers had reviewed it. No licensure arrangement was ever described publicly. | Company-stated |
| Evidence for the therapy class | Rome Foundation Working Team Report, Gastroenterology 2022: more than 30 randomized trials support GI focused CBT in IBS, and meta analyses support gut directed hypnotherapy. A 2025 meta analysis of 12 studies in 1158 patients found it “may improve global symptoms of IBS.” | Peer reviewed |
| What clearance looks like | Mahana Therapeutics won De Novo authorization for Parallel, a digital CBT app for IBS, on November 25, 2020, then 510(k) K211372 on June 2, 2021. metaMe Health’s Regulora, gut directed hypnotherapy, cleared as K211463 on November 24, 2021, citing trial NCT04133519. | Public record |
| Company status | Y Combinator’s page data field ycdc_status reads Inactive. Dealroom marks the company closed. YCDB marks it dead. The domain and the app are gone. | Public record |
Read plainly: Caelum promised a clinically proven replacement for IBS drugs and delivered a diet coaching subscription. Two competitors did the slow thing instead. Mahana licensed a protocol developed over roughly 15 years at King’s College London and leaned on a 558 person randomized trial. metaMe put a registered trial on its 510(k). Both cleared the FDA within about 18 months of each other. Caelum reached the market years earlier and finished behind both on the only ledger that counts.
What to watch
- Nothing from the company. No active website, no app listing, no SEC filing, no announcement since 2018.
- Whether the founders return to the category. Lauren Kelley-Chew went on to Verily Life Sciences, then Levels, then Intuitive.
- The cleared comparators, which now carry the evidentiary burden Caelum described but never took on.
- Any new entrant using the phrase “replacing drugs with software” for a disorder of gut brain interaction. That claim is testable, and the test is a trial.
In their words
“Replacing drugs with software. We use behavioral medicine, delivered digitally, to treat diseases where drugs don’t work.”
Caelum Health company one liner, as recorded by VentureRadar · Company-stated
“Caelum is a digital therapeutic for Irritable Bowel Syndrome. We optimize your diet and figure out which foods are driving your stomach problems.”
Launch HN post by the founders, April 25, 2018 · Company-stated
“We’re a sibling team and have wanted to start a company together since we were kids.”
Launch HN post by the founders, April 25, 2018 · Company-stated
“Caelum provides behavioral health treatments that it says are 3x more effective than prescription drugs, and has pilots with 7 of the top 10 health systems.”
TechCrunch, Y Combinator Summer 2017 Demo Day, August 22, 2017 · Independent
“But unlike FDA approved drugs, registered dietitians and licensed physical therapists your service is not accredited and can’t legally give the advice that it claims to give.”
Commenter on the Launch HN thread, April 2018 · Independent
“We’ve worked with our lawyers on this topic and so far we’re in good shape. But it’s definitely something we need to keep an eye on as we introduce new functionality / try out different marketing.”
Founder reply on the Launch HN thread, April 2018 · Company-stated
“The FDA is currently selectively regulating mobile apps, primarily based on risk categorization. We haven’t been subject to regulation so far, but will of course work with any regulatory bodies if/when that time comes”
Founder reply on the Launch HN thread, April 2018 · Company-stated
“Gut-directed hypnotherapy is a form of medical hypnosis provided by a specially trained clinician.”
Rome Foundation Working Team Report on Brain-Gut Behavior Therapies, Gastroenterology, 2022 · Peer reviewed
Related companies
Sources
- Public recordY Combinator directory entry, batch S17, ycdc_status Inactive
- Public recordSEC EDGAR company and full text search for Caelum Health, no results
- Public recordInternet Archive capture history for caelumhealth.com, 2013 to 2025
- Public recordFDA 510(k) entry K211372, Mahana Parallel digital CBT application for IBS
- Public recordFDA 510(k) entry K211463, Regulora, metaMe Health
- Peer reviewedA Rome Working Team Report on Brain-Gut Behavior Therapies for Disorders of Gut-Brain Interaction
- Peer reviewedAGA Clinical Practice Update on Chronic Gastrointestinal Pain in Disorders of Gut-Brain Interaction
- Peer reviewedDevelopment and Current State of Digital Therapeutics for Irritable Bowel Syndrome, funded by Mahana
- Peer reviewedGut-Directed Hypnotherapy for Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis
- Peer reviewedRandomised clinical trial: gut-directed hypnotherapy is similar to the low FODMAP diet for irritable bowel syndrome
- IndependentAll the companies from Y Combinator’s Summer 2017 Demo Day, Day 2
- IndependentLaunch HN: Caelum Health (YC S17), full comment thread
- IndependentCBT digital therapeutic for IBS patients receives FDA De Novo clearance
- IndependentIBS treatment gains FDA De Novo clearance
- IndependentCaelum Health Incorporated profile, status closed
- IndependentCaelum Health company profile, founders and founded date
- IndependentCaelum Health record with the full company one liner
- IndependentLauren Kelley-Chew profile listing Caelum Health and later roles
- CompanyCaelum Health description republished by RocketReach, naming Endure Capital and the Wharton Innovation Fund
Profile researched and written by Healthcare Discovery. Last updated September 29, 2026.
